SK Chemicals’ domestic hemophilia treatment enters U.S. market

On the 27^th, SK Chemicals(CEO Man-hoon Park) announced the final commercialization approval of ‘NBP601,’ a hemophilia treatment, from the U.S. Food and Drug Administration(FDA).

NBP601 is the first drug which acquired the FDA’s commercialization approval as a new biopharmaceutical drug developed by a domestic pharmaceutical company with a biopharmaceutical substance exported to Australian CSL...